Our strategy is to create herpesvirus-based vaccines  and biotherapeutics for use in animals

Our targeted diseases include both economically important livestock diseases and chronic diseases in companion animals that affect both quality and length of life. Our livestock pipeline includes candidates for: Porcine Circovirus 2 (PCV2), African Swine Fever (ASF), Streptococcus suis, and Porcine Reproductive and Respiratory Syndrome (PRRS) in pigs; and bovine respiratory syncytial virus in cattle. The approach we take is to address key gaps in products on the market such as poor efficacy, high cost, or a complete absence of product.

Our platform technology is a benign herpesvirus isolated from cattle. This virus strain has the ability to infect a wide range of domestic animal species, which makes it highly valuable as a delivery vehicle for vaccines and biotherapeutic protein genes. Due to the ability to test candidate veterinary products in their target host relatively early in the development process, and the relative speed at which animal compared to human products are approved, our approach is amenable to flexible and rapid new product development. 

Through collaboration with several research groups, a suite of tuneable herpesvirus-based vector vaccines and biotherapeutics have been developed to address specific veterinary needs. These are based on bovine herpesvirus4 (BoHV-4). The attributes of the platform allow vaccines to specifically target both antibody and T cell immunity, allow multigene insertion and expression, and promote high quality immunological responses over prolonged periods post-immunisation. Through the insertion of genes for functional rather than antigenic proteins high level expression of biotherapeutic proteins can be achieved in the inoculated animal.

Infectious disease


  • T cell based vaccines
  • Cross protective vaccines
  • Mucosal vaccines
  • Immunise in the face of maternal immunity.

Chronic disease


  • Therapeutic protein delivery
  • Animal as a ‘production platform’
  • Cost effective and highly scalable.

Development Process

We use cutting edge molecular techniques to create our vaccines. We are able to progress from a gene target to stocks of vaccine ready for trials in six months.

Other platform attributes include:

  • Able to accommodate large insertions
  • Prior immunity does not prevent product re-administration
  • Genetically attenuated to limit persistence in host
  • Robust and amenable to scale-up.
TVG Process Figure
Figure showing the in vitro stages and the time for construction of an animal vaccine.